[High-throughout detection and analysis of drug-resistance gene mutation for 2465 cases with chronic hepatitis B in Shenzhen].
PMID: 23855124
2013
Zhonghua shi yan he lin chuang bing du xue za zhi
Abstract: The frequency of Lamivudine related mutation was the highest (42.96%), especially on rtL180M (14. 72%), rtL204I (18. 50%), rtL204V (9. 74%).
Clonal analysis of the quasispecies of antiviral-resistant HBV genomes in patients with entecavir resistance during rescue treatment and successful treatment of entecavir resistance with tenofovir.
Abstract: Almost all clones had L180M and M204V 3TC resistance mutations before and during combination therapy.
Abstract: The percentages of detected clones bearing 3TC (rtL180M and rtM204V) and ETV mutations did not change with rescue 3TC+ADV therapy.
Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.
PMID: 23114756
2013
Antimicrobial agents and chemotherapy
Abstract: UDPS detected >=1 LAM resistance mutations (rtL80I/V, rtV173L, rtL180M, rtA181T, and rtM204I/V) in 10 (22%) of the 46 LAM-experienced subjects, including 5 in whom LAM resistance mutations were not identified by Sanger sequencing.
2'-Fluoro-6'-methylene-carbocyclic adenosine phosphoramidate (FMCAP) prodrug: in vitro anti-HBV activity against the lamivudine-entecavir resistant triple mutant and its mechanism of action.
Abstract: FMCA demonstrated significant antiviral activity against wild-type as well as lamivudine-entecavir resistant triple mutant (L180M+M204V+S202G).
Abstract: Novel 2'-fluoro-6'-methylene-carbocyclic adenosine (FMCA) monophosphate prodrug (FMCAP) was synthesized and evaluated for its in vitro anti-HBV potency against a lamivudine-entecavir resistant clone (L180M+M204V+S202G).
A novel method for the analysis of drug-resistant phenotypes of hepatitis B virus.
PMID: 23403838
2013
International journal of molecular medicine
Abstract: A novel resistance test method was developed by co-transfection with pHBV1.3-XhoI and -rtL180M/M204V and treatment with various NA concentrations.
Abstract: Different bands composed of pHBV1.3-XhoI or -rtL180M/M204V were used to distinguish NA susceptibility.
Abstract: The bands composed of pHBV1.3 were more sharply reduced by lamivudine (LMV) than -rtL180M/M204V.
High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
Abstract: Both mutations, especially mutation rtM204V, were most often accompanied by compensatory mutations rtV173L and rtL180M but also by mutations conferring entecavir (n = 5) or adefovir resistance (n = 4).
Characterization of antiviral resistance mutations among the Eastern Indian Hepatitis B virus infected population.
Abstract: Notably, classical antiviral resistance mutations (rtL80I/V-rtI169T-rtV173L-rtL180M-rtA181T/V/S-rtT184A/S/G/C-rtA194T-rtS202C /G/I -rtM204V/I-rtN236T-rtM250V) were n
Combination of allele-specific detection techniques to quantify minority resistance variants in hepatitis B infection: a novel approach.
PMID: 23454647
2013
Journal of virological methods
Discussion: In summary, the allele-specific quantitative PCR described here, which uses a combination of locked nucleic acid primers and a minor groove binder probe, is a highly sensitive, specific, rapid, and inexpensive method for directly measuring minor viral quasispecies of the triple combination mutation rtV173L+rtL180M+rtM204V within one HBV genome.
Discussion: locked nucleic acids (LNAs) and minor groove binders (MGBs), was utilized to increase the specificity of detection of the triple mutation rtV173L+rtL180M+rtM204V in HBV polymerase
Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
Abstract: During the 48-week treatment period, two patients in the ETV monotherapy group had viral breakthrough and the strains were confirmed to be of a variant associated with ETV resistance (rtM204V+ rtL180M+ rtT184G), while one patient receiving LdT plus ADV had viral breakthrough and an LdT-associated resistance mutation (rtM204I) was detected.
Efficacy of entecavir switch therapy in chronic hepatitis B patients with incomplete virological response to telbivudine.
Abstract: Although rtM204I and/or rtL180M was detected in 3 of 7 patients with incomplete virological response to entecavir, none of the patients with HBV DNA<2,000 IU/ml during telbivudine treatment harboured these amino acid substitutions.
HBV mutation literature information.
PMID: 
2013
Zhonghua shi yan he lin chuang bing du xue za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT